Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can fasting patterns rewire metabolism to halt prediabetes?

NCT ID NCT07755982

Disease control Sponsor: Muhammad Aron Pase Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether different intermittent fasting schedules—5:2, alternate-day, and time-restricted eating—can improve blood sugar, cholesterol, inflammation, and body composition in adults with prediabetes. Participants will be randomly assigned to one of three fasting plans or a control diet for 4-6 weeks. The study also looks at how genes may influence individual responses to fasting. The goal is to find which fasting approach offers the most metabolic benefit for people at risk of type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intermittent fasting (three patterns: 5:2, alternate-day, and time-restricted eating)
What this could lead to
If successful, this could identify which intermittent fasting pattern best improves blood sugar, cholesterol, and body composition in people with prediabetes, potentially offering a practical dietary strategy to prevent type 2 diabetes.
What could go wrong
This is a short-term trial (4-6 weeks) with a moderate sample size, so results may not be durable or generalizable. Adherence to fasting can be challenging, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with prediabetes, defined according to ADA criteria (fasting plasma glucose 100-125 mg/dL or 2-hour postprandial glucose 140-199 mg/dL). 2. Willing to follow the fasting/diet intervention protocol for 4-6 weeks (depending on the study duration). 3. Signing informed consent and willing to be randomized into one of 3 intervention groups (Monday-Thursday Fasting/5:2, Alternate-Day Fasting/ADF, or Time-Restricted Fasting/IF). Exclusion Criteria 1. Diagnosis of type 2 diabetes mellitus. 2. Currently undergoing antidiabetic drug therapy (e.g., metformin, sulfonylurea, insulin). 3. Has a severe chronic disease (kidney failure, liver failure, heart failure, or eating disorder). 4. Pregnancy or breastfeeding. 5. History of eating disorders (anorexia nervosa, bulimia nervosa, or binge eating disorder). 6. Taking medications that affect glucose metabolism (e.g., systemic steroids, atypical antipsychotics, etc.). Diagnosis of type 2 diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-diabetic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glucose intolerance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-diabetic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Internal Medicine - Endocrinology Division, Faculty of Medicine, Universitas Sumatera Utara / RSUP H. Adam Malik Medan

    Medan, North Sumatera, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.